Hyperglycemia during childhood cancer therapy: Incidence, implications, and impact on outcomes

Allison Grimes, Ashraf Mohamed, Jenna Sopfe, Rachel Hill, Jane Lynch

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

Hyperglycemia is a known complication of therapies used in the treatment of childhood cancer, particularly glucocorticoids and asparaginase. It has been linked to increased infection and reduced survival. With more limited data on hyperglycemia during childhood cancer treatment compared with adult cancer, impact on outcomes is less clear in this population. As additional glycemic-altering cancer agents including immune checkpoint inhibitors and targeted therapies make their way into pediatric cancer treatment, there is a more pressing need to better understand the mechanisms, risk factors, and adverse effects of hyperglycemia on the child with cancer. Thus, we utilized a systematic approach to review the current understanding of the incidence, implications, and outcomes of hyperglycemia during childhood cancer therapy.

Original languageEnglish (US)
Pages (from-to)132-138
Number of pages7
JournalJournal of the National Cancer Institute - Monographs
Volume2019
Issue number54
DOIs
StatePublished - Sep 1 2019

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Hyperglycemia during childhood cancer therapy: Incidence, implications, and impact on outcomes'. Together they form a unique fingerprint.

Cite this